BioLineRx Ltd.
做多
已更新

BLRX-BREAKOUT-UPDATE

389
BLRX had a strong rally today and it's just getting started.

In the related idea my price target was $1.34.

Today's high was $1.78

Check out the weekly chart:

快照

Photo Finish.

$1.34 was 1.618 extension level from Waves 1 & 2.

Since the price-action broke $1.34 we will have an extended 3rd wave.

I expect a very strong rally tomorrow, I will update in the morning before the open to confirm.

Target is hard to predict since its impossible to know what level extending waves will terminate.

I will keep a close eye on the price-action.

Will update.

-AB






注释
As expected, a very strong rally today!
注释
快照
注释
We got a big runway...
注释
Reminder this is a WEEKLY chart...

Meaning this move is far from over...
注释
快照
注释
Buckle up!
注释
快照
注释
Target $2.24 (Sell Half)

Trade Price: 1.049
注释
快照
注释
快照
注释
Bull Flag
注释
BLRX will rally again tomorrow.
注释
快照
注释
BLRX is about to rally again...
注释
BLRX continued to consolidate today.

Staying the course...
注释
快照
注释
快照
注释
Near-Term Target: $2.13
注释
快照
注释
Primary Wave 1 Complete
注释
快照
注释
03:21 PM EDT, 10/22/2018 (MT Newswires) -- Oppenheimer has kept its outperform rating on BioLineRx (BLRX) with a price target of $3, betting on BL-8040's commercial opportunity as a stem cell mobilizer after top-line data from the COMBAT/KEYNOTE-202 trial of BL-8040 in combination with pembrolizumab in advanced pancreatic cancer showed modest response rate.
"Given the combination's favorable safety profile, BioLineRx and Merck (MRK) are testing a triplet combination including chemotherapy in an effort to increase response rate," analyst Mark Breidenbach said in a note.
"While we believe the triplet combination is worth testing, our valuation of BioLineRx still remains focused on BL-8040's commercial opportunity as a stem cell mobilizer."
注释
快照
注释
快照
注释
Breakout Imminent
注释
快照

免责声明

这些信息和出版物并非旨在提供,也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。